April 28, 2026 - The pharmaceutical manufacturing sector is undergoing a quiet revolution. As API demand surges driven by patent cliffs, biosimilar competition, and growing global drug consumption, contract development and manufacturing organizations (CDMOs) are turning to continuous flow (CF) technology to solve longstanding production challenges. Recent announcements from Eurofins CDMO Alphora, AGC Pharma Chemicals, and Chugai Pharmaceutical signal that the industry is entering a new phase of manufacturing innovation - one where process intensification, flexibility, and efficiency define competitive advantage.
Continuous flow manufacturing - also known as flow chemistry - involves conducting chemical reactions in a continuously flowing stream rather than in traditional batch reactors. The approach offers several critical advantages for API production: enhanced process control through precise temperature and residence time management, improved safety by minimizing the volume of hazardous intermediates present at any given time, greater reproducibility and scalability, and reduced environmental footprint through lower solvent consumption and waste generation.
For decades, continuous flow technology was largely confined to academic laboratories and specialty fine chemical production. But a confluence of factors - tightening regulatory expectations, rising demand for complex molecules, supply chain disruptions, and the need for cost-effective production at commercial scale - has driven CDMOs to integrate CF technology into their core manufacturing operations.
On April 16, 2026, Eurofins CDMO Alphora announced the expansion of its API manufacturing capabilities through the integration of advanced, custom-built continuous flow technology at its operations in Mississauga, Ontario. The new CF equipment line was developed in-house by Eurofins CDMO Alphora scientists in collaboration with a local university, and the project received advisory services and R&D funding support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
The technology targets complex manufacturing processes that are traditionally difficult to scale effectively in batch mode. According to the company, the CF system provides enhanced process control, improved safety, and greater production agility, resulting in more robust and sustainable API manufacturing. For pharmaceutical sponsors, this translates to shorter development timelines, reduced batch failures, and more predictable commercial-scale production.
The Eurofins announcement is notable for its emphasis on in-house development and academic collaboration. Rather than licensing third-party flow chemistry equipment, the CDMO built its own system tailored to the specific challenges of complex small molecule API synthesis. This approach allows for greater customization and optimization, but also requires significant investment in engineering expertise and process development capabilities.
The growing importance of advanced manufacturing capabilities in the CDMO sector was underscored by the 2026 CDMO Leadership Awards, where AGC Pharma Chemicals was named Best in Class in four categories within the Small/Mid-Sized Small Molecule API CDMO segment. The awards, co-hosted by Outsourced Pharma and Life Science Connect with analysis and validation by the Tufts Center for the Study of Drug Development (Tufts CSDD), are based on evaluations by pharmaceutical and biopharmaceutical clients who worked with CDMOs in the prior two years.
AGC's recognized strengths - including highly specialized and responsive staff, transparent client relationships, effective use of advanced technologies, and flexible scaling support - reflect the attributes that pharmaceutical sponsors increasingly demand from their CDMO partners. The company provides cGMP services across Japan, the United States, and Europe, covering small molecule APIs, agrochemicals, biopharmaceuticals, and gene and cell therapies.
The award highlights a broader industry trend: as the CDMO market matures, differentiation is shifting from pure capacity to integrated technical capabilities, collaborative project management, and the ability to support seamless transitions from development to commercial scale. Continuous flow technology is one of the key tools enabling this differentiation.
Another indicator of manufacturing innovation came from Chugai Pharmaceutical, whose Fujieda Plant's FJ3 API manufacturing building received the 2026 Facility of the Year Awards (FOYA) from the International Society for Pharmaceutical Engineering (ISPE) in the Honorable Mention category. The facility was recognized for its "Dual Manufacturing Capability" design, which enables flexible and efficient production of both macrocyclic peptide APIs - a new drug discovery modality - and conventional small molecule APIs within shared facilities.
The FJ3 facility uses Chugai's proprietary pharmaceutical technology platform and represents a strategic response to the growing importance of peptide and macrocyclic drug modalities in the pharmaceutical pipeline. As the industry moves beyond traditional small molecules and monoclonal antibodies toward more complex modalities - including peptides, oligonucleotides, and antibody-drug conjugates (ADCs) - manufacturing facilities must be designed for maximum flexibility.
The ISPE recognition validates the concept of dual-modality manufacturing, which allows CDMOs and innovators to maximize asset utilization and respond more quickly to shifting pipeline demands.
These manufacturing innovations are unfolding against a backdrop of rapid market growth. The Pharmaceutical CDMO 2.0 market is expected to grow from $173.55 billion in 2025 to $186.65 billion in 2026, reaching $272.85 billion by 2031 at a 7.89% CAGR. The API CDMO segment specifically grew from $115.66 billion in 2025 to $126.61 billion in 2026 and is forecast to reach $221.15 billion by 2032.
Several drivers are fueling this growth. The wave of biologic and small molecule patent expirations through 2030 is creating massive demand for generic and biosimilar API production. Geopolitical considerations - including supply chain diversification away from concentrated manufacturing regions - are reshaping sourcing strategies. And the increasing complexity of drug modalities, from ADCs to oligonucleotides to GLP-1 receptor agonists, demands specialized manufacturing capabilities that many pharmaceutical companies prefer to access through outsourcing.
Technology Investment Is No Longer Optional. As leading CDMOs integrate continuous flow, process analytical technology (PAT), and advanced automation, suppliers without comparable capabilities risk being left behind. The bar for quality, consistency, and process control continues to rise.
Flexibility Creates Value. The ability to produce multiple modalities - small molecules, peptides, ADC linkers and payloads - within flexible manufacturing assets is increasingly valued. Suppliers who can offer this versatility command premium partnerships.
Academic-Industry Collaboration Accelerates Innovation. The Eurofins example demonstrates that CDMOs can develop proprietary manufacturing technologies through university partnerships, often supported by government R&D funding programs. Suppliers should explore similar collaborations to advance their own process capabilities.
Geographic Diversification Matters. With CDMO operations expanding across North America, Europe, and Asia, suppliers with multi-regional manufacturing presence or the ability to support technology transfer across geographies are better positioned to capture global demand.
The pharmaceutical manufacturing sector stands at an inflection point. Continuous flow technology, once a niche innovation, is becoming a core competency for competitive CDMOs. Combined with advances in process analytical technology, digital manufacturing, and modular facility design, these innovations are reshaping the economics and capabilities of API production.
For pharmaceutical sponsors, the expanding toolkit of manufacturing technologies means more options, better quality, and faster timelines. For CDMOs and API suppliers, it means the race is on to invest in the capabilities that will define the next decade of pharmaceutical manufacturing excellence.
